Stifel raised the firm’s price target on ResMed (RMD) to $265 from $260 and keeps a Hold rating on the shares following fiscal Q2 results. While the firm calls it a “good quarter,” it also highlight what it calls “a couple blemishes.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD: